Global Health

  • Viewing accessible and affordable health care as a universal right, for 20 years ICCR members have been advocating for the equitable access and affordability of life-saving medicines in emerging markets where poor public health exerts downward pressure on growth. From pandemic diseases, to neglected tropical diseases (NTDs) and non-communicable diseases (NCDs), ICCR members engage leading pharmaceutical companies in an effort to reduce the disease burden borne by these communities and to promote value-creating behavior and innovative health programs to help resolve some of the world's most intractable diseases. 

    Featured ICCR Initiative

    Pediatric HIV/AIDS formulations. Of the 3.4 million children living with HIV, only 562,000 currently have access to the medicines they need. 

    Featured Websites

    The Access to Medicines Index
    :  The Access to Medicine Index ranks pharmaceutical companies’ efforts to improve access to medicine in developing countries.   

    The Medicines Patent Pool: The MPP aims to lower the prices of HIV medicines and facilitate the development of better-adapted HIV medicines in developing countries. See more:  


    Featured Resources

    Public Health, Human Rights and Faith Organizations Question State Department Pressure Against Global Access to Medicines Initiatives

    ICCR's Statement of Principles and Recommended Corporate Practices to Promote Global Health

    These Principles are an articulation of ICCR's position on corporate responsibility regarding global health, along with our recommended best practices. We welcome affirmation of these Principles and practices by all stakeholders.

    Closing the Gaps in Global Health Care. How ICCR is helping promote the equitable access to and affordability of life-saving medicines in emerging markets.

    Shareholders Applaud Viiv

    ICCR members applaud Viiv's decision to contribute an important patent to the Medicines Patent Pool.

    New Strategies for Global Health

    ICCR members are pursuing multiple strategies to increase access to affordable medicines, including transparent and accountable public/private partnerships.

    See more

    Making Clinical Trials Count

    AllTrials: Make clinical trials count


    Our Quarterly Newsletter

    * indicates required